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MHC class II molecules (MHC-II) present peptides to
T helper cells to facilitate immune responses and are
strongly linked to autoimmune diseases. To unravel
processes controlling MHC-II antigen presentation,
we performed a genome-wide flow cytometry-based
RNAi screen detecting MHC-II expression and pep-
tide loading followed by additional high-throughput
assays. All data sets were integrated to answer two
fundamental questions: what regulates tissue-
specific MHC-II transcription, and what controls
MHC-II transport in dendritic cells?MHC-II transcrip-
tion was controlled by nine regulators acting in feed-
back networks with higher-order control by signaling
pathways, including TGFb. MHC-II transport was
controlled by the GTPase ARL14/ARF7, which
recruits the motor myosin 1E via an effector protein
ARF7EP. This complex controls movement ofMHC-II
vesicles along the actin cytoskeleton in human
dendritic cells (DCs). These genome-wide systems
analyses have thus identified factors and pathways
controlling MHC-II transcription and transport,
defining targets for manipulation of MHC-II antigen
presentation in infection and autoimmunity.INTRODUCTION
Major histocompatibility complex class II molecules (MHC-II)
present peptides to CD4+ T cells that initiate and control immune
responses. The expression of MHC-II is mostly restricted to
professional antigen-presenting cells (APCs), such as B cells
and dendritic cells (DCs), and is controlled by a transcriptional268 Cell 145, 268–283, April 15, 2011 ª2011 Elsevier Inc.complex that includes the MHC-II transactivator CIITA (Reith
et al., 2005). Careful regulation of expression is needed to
prevent uncontrolled immune responses. Various allelic forms
of MHC-II are associated with autoimmune diseases (Chaplin
and Kemp, 1988). The successful presentation of peptides at
the cell surface involves a series of subcellular events. In the
ER, MHC-II associates with the invariant chain (Ii) that fills the
peptide-binding groove and mediates transport to late endoso-
mal compartments called MHC-II compartments (MIICs)
(Neefjes et al., 1990; Roche and Cresswell, 1990). There, Ii is
degraded, leaving a fragment called CLIP in the peptide-binding
groove of MHC-II (Riberdy et al., 1992). In parallel, endocytosed
antigens are degraded into peptides, which compete with CLIP
for binding to MHC-II in a process catalyzed by the chaperone
HLA-DM (DM) (Denzin et al., 1996; Sloan et al., 1995) in the intra-
luminal vesicles of theMIIC (Zwart et al., 2005). Ultimately, MHC-
II-containing vesicles and tubules fuse with the plasma
membrane (Boes et al., 2002; Chow et al., 2002; Wubbolts
et al., 1996) to present the peptide-loaded MHC-II to CD4+
T cells.
Various factors controllingMHC-II expression have been iden-
tified, such as cytokines that can inhibit (IL-10) (Koppelman et al.,
1997) or upregulate (interferon-g) (Steimle et al., 1994) MHC-II
expression. Certain activation signals, such as TLR signaling,
can also upregulate its expression in B cells and DCs (Blander
and Medzhitov, 2006). IL-10 signaling may upregulate MARCH I,
which ubiquitinates and shortens MHC-II half-life (Thibodeau
et al., 2008). Other factors such as pH (Ziegler and Unanue,
1982), kinases (Anderson and Roche, 1998), and cholesterol
(Kuipers et al., 2005) affect MHC-II expression and antigen
presentation.
As a first step toward a systems understanding of MHC-II
antigen presentation, we performed a multidimensional RNAi
screen in which we investigated cell surface expression of
MHC-II, as well as peptide loading, transcriptional control, and
intracellular distribution in an integrated manner. Combining
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Figure 1. A Genome-wide Flow Cytometry-Based RNAi Screen
(A) MelJuSo transfected with siRNA were analyzed for surface expression of peptide- versus CLIP-loaded MHC-II by high-throughput flow cytometry using
monoclonal antibodies (L243-Cy3 and CerCLIP-Cy5). The graphs show representative Z scores of siRNAs without effect (jzj < 3; black line), untreated cells
(green), HLA-DM-silencing (orange), and candidates after normalization (jzj > 3; blue). Inlay in the CerCLIP plot shows the Z0 factor for the analysis of the kinase
sublibrary, representing the detection window between negative (blue) and positive controls (red).
(B) Scheme showing the different confirmation steps in the screening procedure resulting in 276 candidate genes influencing MHC-II expression and peptide
loading. Indicated is the distribution of four phenotypes detected by flow cytometry. See also Table S1 and Table S2.these phenotypic analyses yielded factors and pathways
controlling MHC-II transcription and transport in DCs and
defined targets for manipulation of MHC-II antigen presentation
in infection and autoimmunity.
RESULTS
Genome-wide RNAi Screen Identifies 276 Candidate
GenesAffectingMHC-II Expression andPeptide Loading
MHC-II is selectively expressed by APCs. To identify proteins
and networks involved in MHC-II expression and peptide
loading, we selected the human melanoma cell line MelJuSo,
which expresses peptide-loaded MHC-II and all components
required for MHC-II antigen presentation (Wubbolts et al.,1996). Whereas MelJuSo is not an immune cell type, it does
express many immune-specific genes and proteins controlling
MHC-II transport similar to DCs. APCs express Toll-like recep-
tors (TLRs) recognizing double-stranded siRNA, resulting in
activation signals that might increase MHC-II expression
(Agrawal and Kandimalla, 2004; Reynolds et al., 2006). MelJuSo
lacks these TLRs and in addition exhibits transfection efficien-
cies greater than 95%, as well as stable MHC-II expression
and peptide loading capacity (data not shown). These features,
which are essential for reliable RNAi screens, are not shared
by any primary APC tested.
To visualize the effects of gene knockdown onMHC-II expres-
sion and peptide loading, we used two monoclonal antibodies
(Figure 1A): Cy5-conjugated CerCLIP, which recognizes humanCell 145, 268–283, April 15, 2011 ª2011 Elsevier Inc. 269
MHC-II loaded with the residual Ii-derived CLIP fragment, and
Cy3-conjugated L243, which recognizes peptide-loadedMHC-II
(called HLA-DR). CLIP-loaded MHC-II reflects an inefficiency of
the loading of antigenic peptide on the mature receptor
(Denzin et al., 1994), whereas L243 detects correctly loaded
MHC-II on the plasma membrane (Lampson and Levy, 1980).
MelJuSo cells were transfected with pools of siRNAs (four
duplexes per target gene) in 96-well format targeting 21,245
human genes in total. Three days posttransfection, cells were
analyzed by flow cytometry to determine peptide loading as
well as expression levels of MHC-II. The primary screen (per-
formed in triplicate) achieved an excellent ‘‘screening window’’
(difference of negative and positive control) defined by the Z0
factor (Zhang et al., 1999). All parts yielded Z0 > 0.5 (Figure 1A;
Z0 for the kinase sublibrary). Results were Z score normalized.
Genes whose silencing resulted in a change of L243 or CerCLIP
staining by jzj > 3 (p < 0.0027) were considered candidates for
follow up. These genes were rescreened in triplicate, resulting
in 789 candidate proteins with potential functions in controlling
MHC-II expression and peptide loading (Figure 1B).
To determine which of the 789 candidates identified in the
screen were expressed in APCs, we performed microarray
gene expression analysis on human primary monocytes, mono-
cyte-derived (activated and immature) DCs, and naive or CD40L-
activated B cells (Table S1 available online). Of the candidate
genes identified in MelJuSo cells, 532 genes were expressed
in one ormore human primary APC type. Correcting for off-target
effects (see Experimental Procedures) resulted in 276 confirmed
candidates (Table S2). These candidates could be divided into
four groups based on differential staining with L243 or CerCLIP,
which allowed the distinction between effects onMHC-II expres-
sion versus effects on peptide loading, respectively. Most candi-
date proteins identified in the screen appeared to affect MHC-II
surface expression; only 45 genes specifically affected peptide
loading (CLIP up; Figure 1B).
Candidate Proteins Include Known MHC-II
Pathway Components and Proteins Associated
with Autoimmunity
To annotate the function of the 276 identified genes, we used
database tools to determine tissue distribution, potential func-
tion, association with autoimmune diseases, and established
function in the MHC-II antigen presentation pathway. First, as
a validation of our method, we interrogated the data set for
proteins already known to be involved in MHC-II antigen presen-
tation. Thirteen candidates have been reported in literature to
control MHC-II antigen presentation (Figure 2A, green/yellow
proteins), including the MHC-II transcriptional regulator CIITA,
the HLA-DRA and DRB chains, DM, and the IL-10 receptor.
Another set of 13 proteins might indirectly correlate to the
pathway through inhibitors or as targets of pathogenic immune
regulators (Figure 2A, blue proteins). For example, FK506-
binding protein 3 (FKBP3) may be the target of FK506 (Imai
et al., 2007). The target(s) for general kinase inhibitor Staurospor-
ine (Anderson and Roche, 1998) can be included in the 28 serine/
threonine kinases that we identified in our screen. Also, the
immunodeficiency virus (HIV) protein Tat has been postulated
to control HIV-Tat interacting protein (HTATIP) (Kamine et al.,270 Cell 145, 268–283, April 15, 2011 ª2011 Elsevier Inc.1996) (Figure 2A), whichwe picked up in our screen as a regulator
of MHC-II peptide loading. Hence, some 10% (26 of 276) of our
primary screen candidates have already been implicated in
controlling MHC-II expression and peptide loading. In our initial
screen, however, we did not identify all factors that had been
reported in literature to control MHC-II function. We thus re-
tested these separately, which revealed that most of them
yielded effects below our cut-off of jzj > 3 (Figure S1).
Second, to determine which candidate genes were selectively
expressed in immune tissues, we interrogated a gene expression
database of 79 human tissues (Wu et al., 2009) and compared
expression levels of each candidate between immune and other
tissues. The expression of CIITA is limited to antigen-presenting
cells; therefore we used its expression as a standard for immune
specificity (Figure 2B). Sixty-nine of the 276 candidates identified
by the RNAi screen exhibited selective expression in immune
tissues (Table S1).
Another interesting group in which some of our candidates
could be placed was associated with autoimmunity. Genetic
association studies have revealed that MHC-II is the strongest
autoimmunity-associated factor (Chaplin and Kemp, 1988),
possibly triggering the immune response by presenting autoan-
tigens. Comparing our candidates involved in MHC-II regulation
with a database containing genes linked to autoimmune
diseases (http://geneticassociationdb.nih.gov) showed that
8% (21 of 276) were associated with autoimmune diseases (Fig-
ure 2C). This association, together with their immune tissue-
specific expression pattern, makes some of them attractive
therapeutic targets for manipulating MHC-II function.
A standard protocol in genome-wide screening is pathway
analysis based on literature. We first subclustered candidates
into four groups based on their flow cytometry parameters
(Figure 1B) before functional annotation by Ingenuity Pathway
Analysis (http://www.ingenuity.com; Figure 2D and Table S2).
Many enzyme classes are found to be involved inMHC-II antigen
presentation, but the majority of genes had no ascribed function.
The four groups were then analyzed by Ingenuity Pathways
Analysis and STRING (Snel et al., 2000) for established protein
interactions and yielded several networks consisting of anno-
tated proteins only (Figure S2). Analysis of these networks
revealed clusters of proteins already known to be involved in
MHC-II antigen presentation. No novel clusters regulating
MHC-II became apparent from this network analysis. As most
proteins had unknown functions, these pathways only covered
a small fraction of candidate proteins. Hence, network analysis
using different database tools was unsatisfactory in terms of
describing the systems biology of MHC-II antigen presentation.
Therefore, we aimed at placing candidates in functional
networks following secondary high-throughput screens. We
broke down MHC-II antigen presentation in three processes:
(1) peptide loading, (2) transcriptional regulation, and (3) the
general cell biology of MHC-II. The latter category consists of
the assembly, intracellular transport, processing in the MIIC,
and endo- and exocytosis. Factors affecting peptide loading
were already identified by the antibody CerCLIP in the primary
screen.
After genome-wide screening, we were able to confirm our
strategy by identifying known members of the MHC-II pathway.
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Figure 2. Candidate Gene Annotation
(A) A literature-based model representing proteins directly (yellow) and indirectly (blue) involved in the MHC-II pathway (green). See also Figure S1. EE, early
endosome; MIIC, MHC class II-containing compartment; Ii, invariant chain.
(B) Gene expression ratios of the candidate genes in the primary human immune cells (1) used in our selection procedure (Figure 1B) and immune tissues (2) versus
nonimmune tissues (3).Gray areas indicate absenceof probeson theexpression arrays. Expression levels of (2) and (3)wereobtained from theBioGPSapplication.
(C) Genes from the screen that are associated to autoimmune diseases based on the Genetic Association Database.
(D)Functionalannotationof thecandidategenes involved in thevariouseffectsonMHC-II antigenpresentation.Annotation retrieved fromIngenuityPathwaysAnalysis.
See also Figure S2 and Table S1 and Table S2.
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Furthermore, we have highlighted interesting therapy targets dis-
playing immune-tissue specific expression and association to
autoimmune diseases. Secondary high-throughput assays are
needed to decipher the candidates involved in the transcriptional
regulation and general cell biology of MHC-II.
Nine Candidates Are Implicated in Transcriptional
and Higher-Order Control of MHC-II Expression
MHC-II mRNA expression is controlled by CIITA. To determine
whether the 276 candidate genes identified in the earlier RNAi
screen affectedMHC-II transcription, we silenced the 276 candi-
dates in MelJuSo cells and performed quantitative PCR for
mRNA of MHC-II (HLA-DRA), CIITA, and Ii. To check whether
the candidates from our screen controlled the entire MHC locus,
MHC class I transcription (HLA-A/B/C) was assessed (Horton
et al., 2004).
The silencing of nine candidate proteins affected transcription
of one or several of the tested genes (Figure 3A and Table S3).
Silencing of three candidate genes (CIITA itself, RMND5B, and
PLEKHA4) downregulated CIITA and HLA-DR mRNA levels:
the protein RMND5B has an unknown function, and PLEKHA4
has so far only been described as a phosphoinositide-binding
protein. The silencing of three other genes (KIAA1007 [CNOT1],
CDCA3, and MAPK1) upregulated both CIITA and HLA-DR tran-
scription. CNOT1 is part of a transcription regulatory complex
called CCR4-NOT. This complex also contains another protein
identified in our primary screen called CNOT2. MAPK1 is a key
signaling intermediate in many well-studied pathways, and the
function of CDCA3 is yet unknown. MAPK1 (and CIITA itself)
were the only genes shown to affect the whole MHC-locus, as
measured by MHC class I (MHC-I) expression.
Knockdown of unknown EFHD2 and HTATIP increased the
expression levels of HLA-DR and Ii. Silencing of only one gene
(IL27RA, the IL-27 receptor) affected MHC-I expression inde-
pendently of CIITA. This probably represents a more locus-
specific effect. IL-27RA has been implicated in Th1-type as
well as innate immune responses. For a full description of the
candidates that affect MHC-II transcription, see Table S3.
These nine candidate genes, including CNOT2, can affect
each others’ expression as well as that of CIITA, HLA-DR, Ii,
and MHC-I. To define potential interconnections, we performed
a ‘‘cross-correlative qPCR’’. Each candidate was silenced, and
the effect on expression of the other candidates was determined
by qPCR (Figure 3B). Most siRNAs affected the expression of
one or more other candidate genes, suggesting that they act in
complex networks (Figure 3C). These networks can be defined
as controlling the CIITA expression (network 1), the MHC
locus (network 2), or the selective transcription of HLA-DR and
Ii (group 3).
We performed literature analysis to define higher-order regula-
tion of the transcriptional network controllingMHC-II expression.
Seven of the candidates affecting MHC-II transcription have
already been annotated to pathways. FLJ22318/RMND5B
(human homolog of yeast required for meiotic muclear division
5B protein), on the other hand, is not functionally annotated,
but an interaction with SMAD4 has been reported (Colland
et al., 2004). SMAD proteins transduce signals from the TGFb
receptor to the nucleus to downregulate MHC-II expression272 Cell 145, 268–283, April 15, 2011 ª2011 Elsevier Inc.(Dong et al., 2001). To understand the role of this unknown
factor, we tested whether RMND5B is involved in TGFb
signaling. Following exposure to TGFb for 3 days, MHC-II was
downregulated in MelJuSo. RMND5B silencing further downre-
gulated MHC-II expression as detected by flow cytometry and
qPCR (Figures 3D and 3E). RMND5B might thus act as an inhib-
itor of SMADs. SMAD4 translocates from cytosol to nucleus
upon TGFb exposure (Shi and Massague´, 2003), which was
also observed for RMND5B in MelJuSo (Figure 3F). Although
we failed to show a direct interaction with SMAD4, we placed
RMND5B in a network controlled by TGFb signaling, which
controls MHC-II expression.
We have defined a transcriptional network controlling MHC-II
expression. Furthermore, we described a network of higher-
order control based on proteins annotated in literature (Fig-
ure 3G; for references, see Figure S3). These networks should,
in principle, explain the immune tissue-selective expression of
MHC-II. The data show that CIITA expression is controlled by
a complex transcriptional feedback mechanism, which in turn
is controlled by a series of general biological processes such
as chromatin modification, the cell cycle, and a number of
different signaling events, including those mediated by TGFb
and RMND5B. The combined input of events presumably
determines the tissue selectivity of MHC-II expression.
Analysis of Networks with Similar Intracellular
MHC-II Distribution Phenotypes Selects Candidates
for In-Depth Study
Nine candidate genes were shown to control the transcription of
MHC-II. This implies that the other 268 candidates could affect
the intracellular distribution of MHC-II. This we evaluated by
microscopy. A clonal MelJuSo cell line expressing MHC-II-GFP
and mCherry-GalT2 (a Golgi marker) was transfected with
siRNAs for the candidates. The nuclei (Hoechst) and early endo-
somes (anti-EEA1) were stained to detect all relevant intracellular
compartments of MHC-II (Figure 4A and Figure S4A). The result-
ing images were processed with CellProfiler software (Carpenter
et al., 2006), which resulted in more than 100 parameters
describing the features of nuclei, endosomes, Golgi, and plasma
membrane. Images were analyzed and scored using automated
image analysis software (CPAnalyst2; see Extended Experi-
mental Procedures for analysis parameters) (Jones et al.,
2009). Particular phenotypes could be characterized in this
manner, e.g., enlargedMHC-II-positive vesicles, MHC-II redistri-
bution to the plasma membrane, clustering or dispersion of early
endosomes, and alteredGolgi structure (Figure 4B). After several
rounds of software training, the minimal number of parameters
(out of the > 100) needed to distinguish the phenotypes was
determined (Figure S4B and Table S4). After Z score normaliza-
tion, the siRNAs giving similar phenotypes were clustered
(Figure 4C). Control siRNAs (positive and nonaffecting) were
clustered in distinct groups, thereby validating our method.
To obtain an overview of our data, we built a network tree inte-
grating information of all the different screens. The fill color of
each gene shows the effect on MHC-II surface expression
(L243, flow cytometry screen), whereas the color of the edge
represents mRNA level changes going from immature (im)DCs
to mature (m)DCs, as found by microarray. The size of the
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Figure 3. MHC-II Transcription Control Networks and Higher-Order Control
(A) The heatmap shows the log-transformed expression values (GAPDH as reference) relative to siControl-treated cells (FLJ22318 = RMND5B; KIAA1007 =
CNOT1). Mean values of four independent experiments are shown. Stars show correlation between L243 phenotype (Table S2) and qPCR.
(B) Upon silencing the genes defined under (A), the effect on the expression levels of the nine genes and the MHC-II factors was determined by qPCR. Confirmed
effects of at least two experiments are shown (green, downregulation; red, upregulation; gray, no effect).
(C) Transcriptional networks deduced from the qPCR data controlling CIITA (1), the MHC locus (2), or MHC-II and Ii expression without CIITA involvement (3).
Intracellular localization of the proteins is represented in different colors. Red arrows, inhibition; green arrows, activation of transcription.
(D) MHC-II expression on RMND5B-silenced MelJuSo cells in presence or absence of TGFb. Mean fluorescence intensity of three experiments plus standard
deviation normalized to control siRNA conditions is plotted. *p < 0.05.
(E) RNA levels of HLA-DR upon RMND5B silencing and TGFb treatment. LOG-transformed expression levels (relative to GAPDH) from two experiments
normalized to control siRNA conditions plus standard deviation are plotted. *p < 0.05.
(F) Intracellular distribution of RMND5B and SMAD4 in MelJuSo in the presence or absence of TGFb. Scale bar, 10 mm.
(G) Higher-order control of the transcriptional network, based on literature and experimental data (red box).
See also Figure S3 and Table S3.
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node correlates to an increase in the relative amount of MHC-II at
the surface, an mDC-like phenotype (Cella et al., 1997; Pierre
et al., 1997). This feature was deduced from the microscopic
analysis (Table S4). Candidate genes grouped in the same
branch of the diagram, due to similar phenotypes generated,
were postulated to act in the same functional pathways. We
set an arbitrary threshold to distinguish four highly homologous
clusters in our tree diagram (distance to root R 153.6, genes
per cluster R 15, indicated by blue lines in Figure 4C; see also
Figure S5). These clusters also included unknown proteins that
might be functionally connected to known proteins present in
the same cluster. These connections may be better understood
after in-depth experimental validation.
To understand the function of the identified clusters, we deter-
mined the enrichment of Gene Ontology (GO) terms. As ex-
pected, all candidates identified by the screens were enriched
for the GO cellular component term ‘‘MHC-II protein complex’’
(p = 0.0028815; Table S5). For a more extensive analysis, we
applied the integrated functional gene network program Human-
net v. 1 (Kim et al., 2008), which combines information from
several expression and protein-protein interaction databases.
We first measured the degree of connectivity between our candi-
dates by the area under the receiver operating characteristic
(ROC) curve (AUC) (Figure S6). The AUC of 0.6175 indicates
that many connected genes (neighbors) also genuinely interact.
Neighbors with a log-likelihood scoreR 1 according to Human-
net and a jzj R 1.645 (p < 0.1) in our original flow cytometry
screen were also included in this analysis (Table S6). These
increased the number of proteins involved in the same functional
pathway. Subsequent GO analysis of the expanded groups indi-
cated that clusters 2 and 4 (Figure 4C) were enriched for ‘‘MHC-II
protein complex’’ (Table S5). When we combined this informa-
tion with the microscopy phenotypes, we noted that the genes
in cluster 4 did not affect MHC-II distribution, whereas those in
cluster 2 showed MHC-II redistribution to the cell surface that
resembles an mDC phenotype (Figure 6A). Cluster 2 has two
areas where the genes cohered (Figure 5A); one was enriched
for GO terms like ‘‘MHC-II protein complex’’ (Figure 5B) and
another for ‘‘cytosolic ribosome’’ terms (cells with reduced intra-
cellular MHC-II [data not shown]).
The definition of clusters combined with functional annotation
predicts connections between candidates within a network. This
allows the addition of genes to these networks, which were not
originally identified in our siRNA screen (for reasons of functional
redundancy, effect below cut-off, etc.). Our integrative bioinfor-
matic approach enables us to select candidates for furtherFigure 4. MHC-II Distribution Control: Automated Image Analysis
(A) MelJuSo stably expressing MHC-II (HLA-DRB1-GFP, green) and a Golg
276 candidate genes and stained for early endosomes (EEA1) in blue and nucleu
(B) Confocal images of all silenced genes were analyzed using CellProfiler and CP
similar phenotypes were manually grouped into several bins for the different fl
computer instruction. The minimal number of descriptive parameters for each gr
(C) Organic view of clustered genes based on phenotype determined by quantita
L243 staining (red, upregulation; green, downregulation). The nodes’ border colo
lower expression). Node size represents a measure of mDC phenotype. A larger n
vesicles. Names in large font indicate selected candidates for further testing in DCs
See also Figure S4, Figure S5, Table S4.biochemical studies based on their predicted functional relation-
ships and effects observed in our various screens.
Six Proteins Involved in MHC-II Redistribution
in Maturing DCs
To test whether our networks indeed predict processes that are
essential in the immune system, we studied MHC-II distribution
in DCs. DCs exposed to maturation signals redistribute MHC-II
molecules and various activation markers from CD63-positive
vesicles to the plasma membrane, enhancing their surface
expression. This is an essential step in the acceleration of
immune responses (Cella et al., 1997; Pierre et al., 1997) (Fig-
ure 6A). MHC-II distribution is visualized in a colocalization pixel
plot of CD63 versus MHC-II (Figure 6A, right). To select candi-
dates that are potentially involved in the control of MHC-II redis-
tribution in DCs, we used the following arguments. First, the
genes should upregulate MHC-II expression at the cell surface
(as in mDCs). Second, if upregulation is caused by silencing,
the candidate should be downregulated in the microarray
analyses from imDC to mDC. Lastly, silencing of genes should
induceMHC-II transport to the plasmamembrane as determined
by microscopy (Figure 4C, Table S1, and Table S2). Nine unre-
lated candidates fulfilled all criteria, and we tested whether
silencing these genes in imDCs could mimic the reduction in
expression following activation and therefore alter the distribu-
tion of MHC-II (Figure 6B).
Four individual shRNA sequences per gene were introduced
into primary humanmonocytes before differentiation into imDCs,
detected by decreased monocyte marker CD14 and increased
DC marker DC-SIGN expression. Typical activation markers for
mDCs remained absent (Figure 6C). Seven out of nine selected
candidates increased CerCLIP and/or MHC-II expression in
imDCs 6 days after shRNA transduction ofmonocytes (Figure 6D
and Figure S7A), similar to the effects in the primary screen.
As controls, we silenced CIITA andDM, obtaining the anticipated
effects on L243 and CerCLIP levels, respectively. Gene silencing
was confirmed by qPCR for representative shRNA constructs
(Figure 6E).
Next, the effect of silencing the nine candidates on the distri-
bution of MHC-II in imDCs was studied by confocal microscopy.
A gallery of representative images is shown in Figure S7B. Six
candidates showed a significant redistribution of MHC-II from
CD63-positive compartments to the plasma membrane, which
mimics the distribution of MHC-II in mDCs (Figure 6F and Fig-
ure S7C). Silencing of undefined proteins FLJ20249 (GPATCH4)
and FLJ22595 (the small GTPase ARL14/ARF7), as well as thei marker (mCherry-GalT2, red) were transfected with siRNA targeting the
s (Hoechst, not shown).
Analyst 2. In the process of ‘‘supervised machine learning,’’ siRNAs resulting in
uorescent channels. Shown are panels with representative images used for
oup was determined.
tive microscopy analysis. The color of the nodes indicates the Z score for the
r indicates the change in mRNA levels upon DC maturation (red, higher; green,
ode is correlated to higher cell membrane MHC-II levels related to intracellular
. Example images of genes from selected clusters are shown. Scale bar, 25 mm.
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Figure 5. MHC-II Distribution Control: Systems Analysis of Biological Pathways
(A) Interaction network of genes from cluster 2 (Figure 4C). Green, high-scoring neighbors with jzjR 1.645 (p = 0.1) in the original flow cytometry screen; blue,
genes from cluster 2. Zoom-in on Box 1 is shown.
(B) Gene Ontology analysis of cellular components from the aggregated genes in Box 1. The colors represent enrichment for specific GO term (yellow to red,
enriched).
See also Figure S6, Table S5, and Table S6.
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transcription factor MAFA, strongly affected localization. Redis-
tribution of MHC-II was also observed for coat protein complex II
protein SEC13L1 (SEC13), Golgi protein GOLPH3-like GPP34R,
and PDCD1LG1 (CD274), a molecule that is widely expressed on
immune cells involved in the regulation of T cell responses.
Our strategy identified proteins controlling MHC-II transport in
imDC that would not have been selected without an unbiased
approach. Silencing these genes generated imDCs with an
mDC-like MHC-II distribution. These proteins control most of
the specific immune responses and may be targets for manipu-
lation aimed at controlling these.
A Pathway of the GTPase ARL14/ARF7 and Actin-Based
Motor Myosin 1E Controls MHC-II Transport in DC
We defined various proteins controlling MHC-II transport in DCs.
One of these, theGTPase ARL14/ARF7, was detected onMHC-II
vesicles in imDCs (Figure 7A) and selected as a starting point for
building a pathway aimed at understanding the molecular basis
of MHC-II transport in DCs. Guanine exchange factors (GEFs)
activating ARF GTPases are specified by SEC7 domains (Casa-
nova, 2007). We scanned the data set of the primary screen (Fig-
ure 1) for proteins containing SEC7 domains that upregulated
MHC-II expression, similar to ARL14/ARF7. Two candidate
GEFs were identified. Their SEC7 domains were expressed as
MBP-tagged proteins for in vitro GTP loading assays of GST-
ARL14/ARF7 and GST-ARF6 as control. Only PSD4/EFA6B/
TIC (selectively expressed in the immune system, Z = 2.22 in
RNAi screen) promoted GTP loading of ARF6, as described
(Derrien et al., 2002), and ARL14/ARF7 (Figure 7B). The PH
domain of PSD4 was produced as GST-fusion protein and was
used in a lipid-binding assay that indicated specificity for various
PIP2 species (Figure 7C). The candidates for controlling MHC-II
transport in DC (Figure 6B) also included a regulatory subunit of
PI3K (PIK3R2) (Deane and Fruman, 2004) and PIP5K1A, which
can generate PIP2. Overexpressed GFP-PIP5K1A localized to
the plasma membrane and partly colocalized with intracellular
MHC-II and ARL14/ARF7-mCherry vesicles in MelJuSo cells
(Figure 7D) and phagosomes (Mao et al., 2009). Collectively,
this reveals part of a pathway where PIP5K1A and PIK3R2 create
PIPs that are required for recruitment or activation of the
GEF PSD4, which activates ARL14/ARF7.
GTPases require effectors to transmit function. We performed
yeast two-hybrid with ARL14/ARF7 as bait to identify C11ORF46
(now called ARF7 effector protein, or ARF7EP) (Table S7). This
29 kDa protein does not have any detectable domains and is
selectively expressed in the immune system. The interaction
was confirmed by isolating ARL14/ARF7 with ARF7EP from
lysates of MelJuSo expressing HA-ARF7EP and RFP-ARL14/
ARF7 (Figure 7E). Immunostaining of MelJuSo cells expressing
both proteins confirmed colocalization of ARL14/ARF7 and
ARF7EP (Figure 7F).
Because ARF7EP does not provide any structural information
that connects it to a biological pathway, we performed pull-down
experiments with GST or GST-ARF7EP in cytosolic extracts of
human PBMCs. Proteins found in the GST-ARF7EP isolate
were identified by mass spectrometry as B-actin and actin-
based motor protein myosin 1E (MYO1E). Pull-down experi-
ments from HEK293T extracts showed specific recovery ofGFP-tagged MYO1E by GST-tagged ARF7EP (Figure 7G).
MYO1E is a single-headed actin-based motor highly expressed
in the immune system. ARL14/ARF7 may connect to the actin
network via ARF7EP-MYO1E to control export of MHC-II. To
test this connection, human imDC were stained with anti-actin
and anti-ARL14/ARF7 antibodies (Figure 7H), revealing ARL14/
ARF7 containing vesicles aligning with actin cables. The interac-
tion between ARF7EP and MYO1E was further confirmed by
immune precipitation from extracts of human PBMC (Figure 7I).
Various assays were integrated with the results of the RNAi
screen to place proteins in one immune-specific pathway of
actin-based control of MHC-II transport in imDC (Figure 7J).
Manipulation of this pathway in imDCs to induce the character-
istic MHC-II transport from intracellular stores to the plasma
membrane could be the result of inactivation of the ARF7GEF
PSD4 by changed behavior of PI3 and PI5 kinases. How these
events are controlled in DCs during activation is unknown. By
extensive data set integration, we defined a pathway controlling
one of the most essential steps in immune cell activation: the
redistribution of MHC-II to the plasma membrane in DCs after
maturation.
DISCUSSION
We describe here the genome-wide analysis of an essential
process in the immune system: antigen presentation by MHC-II.
We identify 276 candidates with only 10% described thus far in
the MHC-II pathway. Twenty-one candidates are linked to auto-
immune diseases. As in our siRNA experiments, these genes
may cause aberrant MHC-II expression in patients, which
requires further experimental validation before consideration
for therapeutic manipulation.
We have developed various methods to place the candidate
genes in the systems of transcriptional and cell biological control
of MHC-II antigen presentation. By flow cytometry, we selected
45 genes affecting peptide loading only, including HLA-DM and
components of the ESCRT machinery that are involved in multi-
vesicular body formation. A limited set of genes could be placed
in networks by computer-based pathway analysis, unlike the
majority of genes, which have an unknown function. This repre-
sents an enigma in high-throughput screening yielding large data
sets and often results in preselecting one gene for in-depth anal-
ysis with limited new understanding of biology.
There are two important unelucidated processes in MHC-II
antigen presentation, which we addressed in our study in detail:
the control of tissue-specific expression of MHC-II and the regu-
lation of MHC-II distribution in DCs. MHC-II expression is
controlled by CIITA. How CIITA, in turn, is regulated is unclear.
We discovered nine transcriptional regulators of MHC-II expres-
sion and performed cross-correlative qPCR to determine their
interrelationships and their effects on CIITA expression. Five of
these regulate the expression levels of CIITA in a complex feed-
back loop involving the (yeast meiosis) factor RMND5B and
MAPK1 that phosphorylates and influences CIITA activity (Voong
et al., 2008). The remaining factors control MHC-II expression
without affecting CIITA levels. This includes the HIV Tat-interact-
ing protein HTATIP, a histone modifier that may mediate Tat
control of MHC-II expression (Kamine et al., 1996; KanazawaCell 145, 268–283, April 15, 2011 ª2011 Elsevier Inc. 277
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et al., 2000). By combining experimental and literature data, we
show that the activities of extracellular signaling, the cell cycle,
and chromatin modifications control the transcriptional network
for immune tissue-restricted MHC-II expression. Of note, patho-
gens also manipulate these pathways; HIV targets HTATIP, and
L. monocytogenes targets SMAD4 (Kamine et al., 1996; Ribet
et al., 2010). Tissue-selective expression of MHC-II is thus
orchestrated by a series of unrelated input signals. The details
of how these cooperate to induce proper MHC-II expression
remain unclear.
To identify proteins controlling MHC-II distribution, we
silenced all candidates, and the effect on MHC-II distribution
was visualized by microscopy. Candidate genes inducing
a similar phenotype are expected to participate in one network,
as illustrated in yeast screens that identified the ESCRT
machinery (Teis et al., 2008). We integrated our phenotypic clus-
ters with databases like Humannet v. 1 to expand our networks
and annotated these using GO analyses. Half of the genes in
these clusters were predicted to control MHC-II trafficking but
will require further experiments to validate their place in
networks.
To select candidates involved in MHC-II redistribution in DCs,
expression and functional RNAi data sets were combined to
define six proteins controlling MHC-II transport. Silencing these
resulted in imDCs with an mDC-like MHC-II distribution. These
six candidates could act in one or parallel pathways.
One candidate, ARL14/ARF7, is a GTPase that is selectively
expressed in immune cells. To build a pathway, we first localized
ARL14/ARF7 on MHC-II compartments in imDC. Using domain
predictions and in vitro assays, we defined the GEF for ARL14/
ARF7 as PSD4. PSD4 contains a PH domain with specificity
for various PIP2 species, which may result from activities of
two other proteins proposed to control MHC-II distribution in
DCs: PIK3R2 and PIP5K1A. Whereas PI(3,5)P2 locates to late
endosomes (Vicinanza et al., 2008), the PH domain of PSD4
has a broader specificity and can therefore not induce selective
targeting of PSD4 to late endosomes. The 60 kDa N-terminal
domain of PSD4 may induce targeting to endosomal vesicles
(Derrien et al., 2002). When detecting PIP2, the PH domain of
PSD4 might position the preceding SEC7 domain correctly for
supporting GTP loading of ARL14/ARF7. To further expand the
network, an interaction of the ARL14/ARF7 effector ARF7EPFigure 6. MHC-II Redistribution in imDCs
(A and F) Immature (imDCs) and maturated (mDCs) DCs (A) or manipulated imDC
nucleus (white, Hoechst) and were analyzed by confocal microscopy. Shown is th
the normalized correlation coefficient indicated. Scale bar, 10 mm.
(B) Selected candidate genes with primary screen phenotype (Table S2) are indi
(C) Cell surface expression levels of monocyte (CD14), DC (DC-SIGN), and matur
donors plus standard deviation relative to levels on imDC. Four individual shRN
(shRNA) have been averaged.
(D) Median Z score of three donors in flow cytometry after silencing candidates in
highlights the cutoff. Stars indicate confirmation of phenotype as observed in Me
construct).
(E) Knockdown levels determined by qPCR represented as normalized RNA lev
constructs are shown per gene. Averages plus standard deviations are plotted.
(F) Representative microscopy images of three confirmed candidates silenced by
colocalization coefficient was normalized to control shRNA-treated cells and det
See also Figure S7.with the actin-based motor MYO1E was defined. This pathway
connects general signaling events to actin-based transport
control of MHC-II compartments in DCs.
Whereas PIK3R2 and PIP5K1A upstream are broadly ex-
pressed proteins, the other proteins in this pathway are more
immune system selective. Of note, another candidate for
controlling MHC-II distribution in DCs, PDCD1LG1 (CD274,
PD-L1), activates PI3K via its receptor PD-1. PD-1 delivers inhib-
itory signals regulating T cell activation and tolerance. Little is
known about PD-L1 signaling (Keir et al., 2008), and this
signaling may be irrelevant in mDC (Breton et al., 2009).
Tissue-selective control of actin-based transport by GTPases
has been shown before for melanosomes where GTPase
RAB27a binds MYO5A via its effector Melanophylin (Seabra
and Coudrier, 2004). MYO1E may be involved in granule secre-
tion (Schietroma et al., 2007) as well as endocytosis by coupling
to dynamin (Krendel et al., 2007). MYO1E may have multiple
functions in actin-based processes, depending on recruitment
to specific locations. We define ARL14/ARF7-ARF7EP as
a MYO1E receptor on MHC-II compartments for actin-based
transport control. How the previously observed interaction
between another actin-based motor MYH9 and MHC-II-associ-
ated Ii contributes to this process is unclear (Vascotto et al.,
2007).
The four remaining proteins controlling MHC-II transport in
imDC could not be placed in this pathway: MAFA is a transcrip-
tion factor for insulin in pancreatic b cells (Olbrot et al., 2002). Our
microarray data do not show any insulin production in DCs
because the transcription cofactors Pdx-1 and NeuroD1 (Cerf,
2006) are not expressed. SEC13L1 (SEC13) is a COPII protein
controlling transport between ER and Golgi (Tang et al., 1997),
which is a nonimmune-specific process in cells. GOLPH3Lmight
have a similar function in the Golgi as GOLPH3 (Dippold et al.,
2009). The function of the fourth protein, GPATCH4, is unknown.
It remains to be elucidated whether and how GPATCH4 could
manipulate MHC-II antigen presentation.
We describe here a genome-wide analysis of molecules acting
on a central controller in the immune system: MHC-II. After a first
candidate selection by flow cytometry, we applied two additional
high-throughput techniques and integrated the data with ex-
pression and protein interaction databases, cross-correlative
qPCR, yeast two-hybrid, and proteomics. We defineds (F) were stained for MHC-II (green), CD63 (blue), actin (red, phalloidin), and
emerge and the colocalization plot per pixel for CD63 versus MHC-II (right) with
cated.
ation markers (CD83, CD40, CD80, and CD86) are plotted as averages of three
A control vectors (shControl) or shRNAs targeting various candidate genes
imDCs plotted for one representative shRNA construct per gene. The gray box
lJuSo cells (black confirmation by > 1 shRNA constructs; gray by one shRNA
els relative to control shRNA-treated cells of one donor. Two representative
n.a., not analyzed.
lentiviral shRNA in imDC with intracellular effects on MHC-II redistribution. The
ermined by CellProfiler. Scale bar, 10 mm.
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a transcriptional network for MHC-II and CIITA and a cell biolog-
ical pathway placing ARL14/ARF7, its effector ARF7EP, and
MYO1E in control of actin-based MHC-II transport in DCs. This
study identifies new targets and pathways for chemical and bio-
logical manipulation of MHC-II expression in various diseases,
including autoimmunity.
EXPERIMENTAL PROCEDURES
siRNA Transfection, Flow Cytometry, and Microarray
Gene silencing was performed in the human melanoma cell line (MelJuSo)
using DharmaFECT transfection reagent #1 and 50 nM siRNA (Human siGe-
nome SMARTpool library, Dharmacon). Three days posttransfection, cells
were analyzed by flow cytometry (BD FACSArray) using L243-Cy3 (Lampson
and Levy, 1980) and CerCLIP-Cy5 (Denzin et al., 1994) monoclonal antibodies.
The data were normalized (cellHTS, Bioconductor) and transformed into
Z scores (Boutros et al., 2006). Expression levels of genes with jzj > 3 were
determined by microarray analysis (Illumina) in primary human monocytes,
DCs, and B cells, isolated and differentiated as previously described (Souwer
et al., 2009; Ten Brinke et al., 2007). Mature DCs were generated by culturing
for 2 days in the presence of 2.5 mg/ml LPS (Invivogen) and 1000 U/ml IFNg
(Immukine, Boehringer Ingelheim). For statistical analysis, p valueswere deter-
mined using the Student’s t test.
Quantitative RT-PCR
Messenger RNA was extracted (mRNA Capture Kit) and reverse transcribed
into cDNA (Transcriptor High Fidelity cDNA Synthesis Kit). The quantitative
RT-PCR was performed using LightCycler 480 SYBR Green 1 Master on the
LightCycler 480 Detection System (all Roche). Quantification was performed
using the comparative CT method (DDCT). Primer sequences are available
upon request.
Confocal Microscopy
Distribution of MHC-II, early endosomes, and Golgi was visualized by confocal
microscopy (Leica AOBS microscope) using MelJuSo stably expressing HLA-
DRB1-GFP, mCherry-GalT2 and was stained with anti-EEA1 (BD transduction
laboratories) and Hoechst (Invitrogen). DCs were stained using Hoechst, Phal-
loidin-Alexa568 (Molecular Probes), anti-ARL14 2C8 (BioConnect), anti-CD63
(NKI-C3), and anti-HLA-DR (Neefjes et al., 1990). Images were analyzed using
CellProfiler 1.0.5811 (Carpenter et al., 2006). CPAnalyst 2 was used to deter-
mine the minimal set of parameters needed to describe the relevant pheno-
types (Jones et al., 2009). The ‘‘Measure Correlation’’ module of CellProfiler
was used to determine the correlation between CD63 and MHC-II. MelJuSo
cells were cultured with 3 ng/ml TGFb for 3 days. Cells were stained with
anti-SMAD4 (Santa Cruz) and anti-RMND5B (Abcam) antibodies. Open andFigure 7. Data-Based Systems Determination of PIP5K-ARL14-MYO1E
(A) Immature human monocyte-derived DCs were fixed and stained for nucleus
(B) In vitro a32P-GTP loading of ARL14/ARF7 and ARF6 by SEC7 domains of predic
the two GTPases. Shown are average and standard deviation of triplicate experi
(C) Phospholipids spotted on a membrane were probed with the GST-purified P
(D) MelJuSo cells were transfected with ARL14/ARF7-RFP and GFP-PIP5K1A, fi
bar, 10 mm.
(E) Immunoprecipitation (IP) of ARL14/ARF7-RFP and HA-ARF7EP expressed
antibodies. Molecular weight standard is indicated. See also Table S7.
(F) Immunofluorescence of MelJuSo expressing ARL14/ARF7-RFP and GFP-AR
(G) Pull-down of GFP-MYO1E expressed in HEK293T with recombinant GST-ARF
with GST and GFP antibodies. Molecular weight standard is indicated.
(H) imDC stained for endogenous actin and ARL14/ARF7 (ARL14.2). Two zoom-
(I) IP of endogenous ARF7EP and MYO1E in human PBMC with anti-ARF7EP
antibodies. Molecular weight standard is indicated.
(J) Summarized pathway of actin-based control of MHC-II in imDC. Red proteins,
and confirmation of the various proteins are indicated. PI kinases create substrate
and MYO1E connect to actin.proprietary software was used for pathway analysis as extensively described
in the Extended Experimental Procedures.
DC Manipulation
Human primary monocytes were transduced with lentiviral particles in the
presence of 4 mg/ml polybrene (Millipore) at aMOI of 2. Viruses were produced
by 293T cells transfected with packaging (pRSVrev, pHCMV-G VSV-G,
pMDLg/pRRE) and pLKO.1shRNA constructs (Open Biosystems, Thermo
Scientific) using Fugene 6 (Roche). Monocytes were subsequently cultured
for 6 days in the presence of 800 U/ml IL-4 and 1000 U/ml GM-CSF (Cellgenix)
to generate imDCs. DC cell surface marker levels were determined by flow cy-
tometry after staining with the following mouse anti-human antibodies: FITC
CD14, APC DC-SIGN, PE HLA-DR (L243), FITC CD83, APC CD40, PE CD80,
and APC CD86 (all from BD).
Pathway-Building Techniques
Yeast two-hybrid was performed at DKFZ (Heidelberg) with ARL14-Q68L
without myristoylation site cloned in pGBT9. ARF7EP was cloned in a bacterial
expression vector as a GST-chimera and purified. Recombinant GST-ARF7EP
and GST as a control were used to fish for endogenous MYO1E from cytosolic
extracts of human PBMCs, and bound fractions were analyzed by mass spec-
trometry. Biochemical GEF assays were performed with purified MBP-tagged
SEC7 domains fromCYTH1 and PSD4 and GST-purified ARL14 or ARF6 using
a32P-GTP. The PH domain of PSD4 was isolated as a GST-PHPH protein from
293T cells and was used to probe phospholipid membranes (tebu-bio). For
antibodies used to immunoprecipitate, see Extended Experimental
Procedures.
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Microarray data has been submitted to ArrayExpress under the accession
number E-MTAB-192.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and seven tables and can be found with this article online at doi:10.
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or anti-GFP (Control). Immunoblots were probed with MYO1E and ARF7EP
candidates from the screen with jzj > 3; blue proteins with jzj < 3. Identification
s for the GEF PSD4 required for ARL14/ARF7 activation. The effector ARF7EP
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